Introduction
============

Toxoplasmosis is a worldwide disease affecting about one-third of the human population ([@B46]). *Toxoplasma gondii*, the causative agent of toxoplasmosis, is an obligate intracellular parasite that infects distinct host cells ([@B46]). Macrophages are key players of the host immune system and are able to control *T. gondii* replication following activation by interferon gamma and a second signal provide by LPS or TNF-α ([@B1]; [@B42]). One of the main components of antimicrobial activities of activated macrophages is the production of NO through the induction of iNOS ([@B30]). Generation of NO has been implicated in control of chronic toxoplasmosis ([@B8]; [@B26]; [@B38]; [@B36]). However, *T. gondii* coevolved with its host and evasion mechanisms have emerged to thwart many of the effectors of activated macrophages. Included among these virulence factors are proteins released from rhoptries that block innate immunity ([@B24]) and dense granules that alter host cell transcription ([@B21]).

During host cell invasion, *T. gondii* secretes contents from specialized secretory organelles including rhoptries and dense granules that have a central role in parasitophorous vacuole formation and host immunity subversion ([@B7]; [@B4]; [@B5]; [@B14]; [@B32]). For example, the ROP5-ROP17-ROP18 complex, which is secreted from rhoptries, blocks the assembly and function of vacuolar-targeted IRGs ([@B37]; [@B45]; [@B2]; [@B35]; [@B14]). Recruitment of IRGs to the vacuole normally results in its destruction and death of the parasite ([@B48]; [@B25]), but ROPs of virulent strains of the parasite are able to phosphorylate key IRG proteins, inhibiting their activity and assembly, protecting *T. gondii* ([@B15]; [@B43]). Proteins from GRA are another important class of virulence factors secreted by *T. gondii* during and after host cell invasion that perform major roles in parasite survival and replication ([@B31]). For example, GRA16 down-modulates host p53 expression changing the cell cycle ([@B4]), while GRA24 causes host p38α activation, leading to a strong proinflammatory response ([@B5]). Recently, another important *T. gondii* virulence factor known as inhibitor of STAT1-dependent transcription (IST) has been described ([@B18]; [@B32]). IST translocates to the host nucleus where it recruits a repressive complex of STAT1 promoters, blocking the IFN-γ dependent transcription, avoiding host cell activation ([@B32]).

Classically activated macrophages produce NO that control *T. gondii* replication ([@B1]; [@B3]; [@B26]). NO is an important microbicidal molecule that is produced by iNOS ([@B44]; [@B47]; [@B28]). It is well known that *T. gondii* evades the cytotoxic effects of NO by inhibiting NO production of activated mice peritoneal macrophages ([@B11]; [@B39], [@B40]; [@B29]). Furthermore, in activated J774-A1 macrophages, infection causes iNOS degradation by the proteasome ([@B33]). Although TGF-β 1 is involved in the inhibition of NO production in infected activated macrophages ([@B40]), the parasite effector responsible for iNOS degradation and NO inhibition still remains elusive. In addition, most of these studies have been done *in vitro* with a single cell type and without comparison of other macrophage cell lines.

Macrophages are an extremely heterogeneous cell population with many subpopulations that behave differently ([@B19]). Thus, *T. gondii* has to deal with many distinct macrophage subpopulations during host infection. To better understand how *T. gondii* copes with NO production of distinct activated macrophages lines, production of this microbicidal molecule and expression of iNOS were compared in two macrophage cell lines after infection. In addition, several previously described virulence factors were also analyzed as possible effectors responsible for NO inhibition of infected activated macrophages. This study reveals intrinsic differences between both macrophage cell lines in activation patterns and mechanisms by which *T. gondii* infection disrupted NO production. Furthermore, previously identified virulence effectors that were tested here did not alter the NO inhibition phenotype detected in both macrophages cell lines, indicating that a novel effector is responsible for the inhibition of this important host microbicidal molecule.

Materials and Methods {#s1}
=====================

Biosecurity and Institutional Safety Procedures
-----------------------------------------------

This study was carried out in accordance with the NIH standard biosecurity and institutional safety procedures of Washington University School of Medicine.

*Toxoplasma gondii* and Cell Culture
------------------------------------

Knockout parasites used in this work were previously generated as reported: RHΔku80 ([@B16]); Δrop5 ([@B2]); Δrop17, Δrop17/18, Δrop18 ([@B14]); ΔTgIST ([@B32]); (Δasp5) ([@B10]); (Δmyr1) ([@B17]). Wild type *T. gondii* tachyzoites, deficient in Ku80 (RHΔku80) and knockout parasites, all of the RH strain, were maintained by serial passage in Human Foreskin Fibroblast (HFF) monolayers. Parasites were released from HFF using a cell scraper (TPP, Switzerland). The cell suspension was passed three times in a 10 ml syringe (BD, United States) with a 22-gauge needle (CML Supply, United States) and it was filtered on a 3 μm Whatman Nuclepore membrane (GE Healthcare Life Sciences, United States).

Human Foreskin Fibroblast cells were obtained from the Boothroyd laboratory at Stanford University. HFF cells and the mouse macrophage cell lines RAW 264.7 (ATCC TIB-71, United States, from BALB/c mice ascites after Abelson murine leukemia virus inoculation) and J774-A1 (ATCC TIB-67, United States, from BALB/c mice ascites after reticulum cell sarcoma inoculation) were cultivated in Dulbecco's modified Eagle's medium (DMEM - Invitrogen, United States) supplemented with 10% HyClone Fetal Bovine Serum (FBS - GE Healthcare Life Sciences, United States), 10 mM glutamine (Thermo Fisher Scientific, United States) and 10 μg/ml gentamicin (Gibco, United States) in an incubator (Thermo Fisher Scientific, United States) at 37°C in 5% CO~2~ atmosphere. Cultures were negative for *Mycoplasma* spp. contamination with the e-Myco plus PCR detection kit (Boca Scientific, United States).

Generation of Δrop16 Knockout Parasites
---------------------------------------

The knockout plasmid construct for *ROP16* was created using the three-fragment Gateway™ recombination system (Invitrogen, United States), joining two constructs homologous to the 5′ and 3′ flanks of *ROP16* with a central HXGPRT expression cassette, as described previously ([@B14]). This plasmid was transfected into RHΔhxgprtΔku80 parasites, and resistant pools were expanded under treatment with mycophenolic acid (15 μg/ml) acid and xanthine (50 μg/ml). After PCR (Applied Biosystems, United States) confirmation of construct integration in the pool, parasites were subcloned by limiting dilution in 96-well plates (TPP, Switzerland) containing confluent monolayers of HFF cells. Clones were identified by visual confirmation of single plaques, screened by PCR to confirm replacement of the coding region of ROP16 with the HXGPRT cassette, expanded by growth on HFF monolayers, and cryo-preserved.

Macrophage Activation and Infection
-----------------------------------

The RAW 264.7 and J774-A1 cells were seeded at the density of 5 × 10^4^ cells per well in 96-well plates, activated with 200 U/ml of recombinant mouse IFN-γ (R&D Systems, United States) and 0.2 μg/ml of LPS from *Escherichia coli* 0111:B4 (Sigma-Aldrich, United States) for 24 h prior of the *T. gondii* infection. After 24 h of activation, cells were washed twice with sterile PBS, DMEM supplemented with 3% FBS was added, cells were infected with a 5 *T. gondii* per macrophage (5:1) ratio and incubated at 37°C for 2 h. The *T. gondii*-macrophage ratio used was determined by previous experiments examining NO production and number of adhered macrophages after 24 h infection. After infection, cells were washed twice in sterile PBS, and DMEM supplemented with 10% FBS with IFN-γ and LPS or these activators and [L]{.smallcaps}-arginine (Sigma-Aldrich, United States) at different concentration, was added. Supernatants were collected at 2, 4, 6, and 24 h after infection for the nitrite assay.

Nitrite Oxide (NO) Production
-----------------------------

The NO produced by macrophages was assayed by the Griess reagent ([@B20]). Briefly, 50 μl of cell supernatant from each well were collected and distributed in 96-well plates and 50 μl of Griess reagent (1:1, 0.1% N-(1-Naphthyl) ethylenediamine dihydrochloride (Sigma-Aldrich, United States) in distilled water and 1% sulfanilamide (Sigma-Aldrich, United States) in 5% phosphoric acid (Sigma-Aldrich, United States) were added. Plates were incubated at room temperature and nitrite was read in a plate reader (BioTek, United States) at 540 nm. The nitrite value was calculated from a calibrated standard curve using sodium nitrite ranging from 0 to 100 μM.

In-Cell-ELISA
-------------

Infection of parental and knockout parasites into RAW 264.7 and J774-A1 macrophages was evaluated after 2 h of challenge in cells seeded in 96-well plates, activated and infected as described. After infection, cells were fixed and permeabilized for 30 min in PBS containing 4% formaldehyde (Polysciences, Inc., United States), 0.05% Triton X-100 (Fisher BioReagents, United States), washed with PBS and blocked for 30 min with 5% FBS and Normal Goat Serum (Sigma-Aldrich, United States) in PBS (FBS-NGS). Cells were incubated for 1 h with anti-RH (SAG1) rabbit antibody diluted 1:2000 in FBS-NGS, washed twice and incubated for 1 h with anti-rabbit HRP conjugated antibody (Life Technology, United States) diluted 1:4000 in FBS-NGS. Cells were washed three times, incubated for 15 min with 100 μl of TMB substrate (BD OptEIA, Thermo Fisher Scientific, United States), reaction stopped with 100 μl of 1M H~2~SO~4~ and the absorbance was read in a plate reader (BioTek, United States) at 450 nm. Non-infected macrophages were used as negative control.

Immunofluorescence Assay
------------------------

RAW 264.7 and J774-A1 macrophages were seeded at the density of 5 × 10^5^ cells per well over coverslips (Fisherbrand, United States) in 24-well plates (TPP, Switzerland), activated and infected as described. Cells were fixed for 30 min with PBS containing 4% formaldehyde, permeabilized for 15 min in PBS containing 0.1% Triton X-100, incubated for 30 min with PBS containing 100 mM of NH~4~Cl (Sigma-Aldrich, United States), and washed three times with PBS containing 1.5% Bovine Serum Albumin (PBS-BSA, Sigma-Aldrich, United States). Cells were incubated for 1 h with anti-iNOS mouse monoclonal antibody (sc-7271, Santa Cruz Biotechnology, United States) diluted 1:100 and anti-RH (SAG1) rabbit antibody diluted 1:2000 in PBS-BSA, washed once in PBS and twice in PBS-BSA and incubated with goat anti-mouse IgG monoclonal antibody conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, United States) diluted 1:200 and goat anti-rabbit IgG monoclonal antibody conjugated to Alexa Fluor 594 (Thermo Fisher Scientific, United States) diluted 1:2000 in PBS-BSA. Coverslips containing cells were mounted with the Prolong Gold antifade reagent with DAPI (Life Technologies, United States) and visualized with a Zeiss Axioskop 2 MOT Plus epifluorescence microscope with a 63× Plan Apochromat lens (numerical aperture of 1.40; Carl Zeiss, Inc., Germany), equipped with an AxioCam MRm camera (Carl Zeiss, Inc., Germany). Images were acquired using Axiovision v4.6 (Carl Zeiss, Inc., Germany) and processed with Adobe Photoshop 6.0 (Adobe Systems Inc., United States).

Cell Analysis
-------------

To quantify the percentage of iNOS positive and iNOS negative cells in infected or non-infected cells, RAW 264.7 and J774-A1 macrophages were seeded in black 96-well cellstar microplates with clear bottom and condensation rings (BioTek, United States), activated and infected as described. Cells were fixed with PBS containing 4% formaldehyde for 15 min, washed three times with PBS and incubated for 15 min with FBS-NGS containing 5 μg/ml of Wheat Germ Agglutinin conjugated to Alexa Fluor 633 (Thermo Fisher Scientific, United States) for total cell staining. Cells were washed twice in PBS and incubated for 1 h with anti-iNOS mouse monoclonal antibody (Santa Cruz Biotechnology, United States) diluted 1:100 in FBS-NGS and anti-RH (SAG1) rabbit antibody diluted 1:10000 in 5% FBS-NGS. Cells were washed twice with PBS and incubated with goat anti-mouse IgG conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, United States) diluted 1:200 and goat anti-rabbit IgG conjugated to Alexa Fluor 594 (Thermo Fisher Scientific, United States) diluted 1:2000 in FBS-NGS. Cell analysis was performed with a Cytation 3 (BioTek, United States) multimode plate imager equipped with Gen5 software and 20× objective.

Western Blot and Densitometry Analysis
--------------------------------------

RAW 264.7 and J774-A1 macrophages were seeded at the density of 2 × 10^6^ cells per well in 6-well plate (TPP, Switzerland), activated and infected as described. Cells were washed once in sterile PBS and lysed with 50 μl of lysing buffer containing 50 mM of Tris--HCL (Sigma-Aldrich, United States), 150 mM NaCl (Sigma-Aldrich, United States), 1% Triton X-100 (Sigma-Aldrich, United States) and protease inhibitor cocktail (Sigma-Aldrich, United States). Protein samples were frozen in liquid nitrogen three times, centrifuged (Eppendorf, Germany) at 5,000 *g*, for 3 min and protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, United States). Samples were diluted 4:1 in 5× Laemmli buffer containing 10 mM of dithiothreitol (Sigma-Aldrich, United States), boiled for 5 min, resolved in 8% polyacrylamide gels (Bio-Rad Laboratories, Inc., United States) by SDS--PAGE, and transferred to nitrocellulose membranes Amersham Protran 0.45 NC (GE Healthcare Life Sciences, United States) for 1 h. Membranes were blocked overnight at 4°C with 5% fat-free milk in PBS 0.1% Tween 20 (Sigma-Aldrich, United States), probed for 1 h with anti-iNOS mouse monoclonal antibody (Santa Cruz Biotechnology, United States) dilute 1:1000 and rabbit anti-β-actin (Cell Signaling Technology, United States) diluted 1:1000 in 5% fat-free milk in PBS 0.1% Tween 20. Membranes were washed with PBS 0.1% Tween 20 and labeled for 1 h with IR dye-conjugated secondary antibodies (LI-COR Biosciences, United States) against mouse and rabbit dilute 1:15000 and visualized on a LiCor Odyssey Imaging System (LI-COR Biosciences, United States). Western blots were quantified using the software ImageJ and intensity values were normalized to β-actin at each time interval.

Statistical Analysis
--------------------

Statistical analyses were conducted with Prism 7 (GraphPad Software Inc., United States), and differences in the means were assessed by one-way or two-way ANOVA with Tukey's multiple comparison post-test, or unpaired Student's *t*-test. *P* ≤ 0.05 was the cutoff considered minimum for significance.

Results
=======

*T. gondii* Inhibits NO Production of Activated Macrophages Independently of Substrate Availability and Cell Type
-----------------------------------------------------------------------------------------------------------------

To evaluate the ability of the parasite to inhibit NO production in different macrophage cell lines, activated J774-A1 or RAW 264.7 cells were infected with *T. gondii* and nitrite production was evaluated in culture supernatant at different time points. Differences in the timing of inhibition of NO production were observed between the two cell lines. In J774-A1 macrophages, inhibition of NO production occurred by 2 h post-infection (**Figure [1A](#F1){ref-type="fig"}**) and was sustained up to 24 h (**Figure [1B](#F1){ref-type="fig"}**). In contrast, inhibition of NO production in RAW 264.7 macrophages occurred only after 6 h post-infection (**Figure [1C](#F1){ref-type="fig"}**) and was sustained up to 24 h (**Figure [1D](#F1){ref-type="fig"}**).

![Nitric oxide (NO) production (nitrite in μM) in activated J774-A1 and RAW 264.7 cells macrophages after *T. gondii* infection. **(A)** NO production of non-infected (Control) or *T. gondii* (RH) infected J774-A1cells at 6 h and **(B)** 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). **(C)** NO production of non-infected (Control) or *T. gondii* (RH) infected RAW 264.7 cells at 6 h and **(D)** 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). ns (not significant), ^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01, ^∗∗∗^*P* ≤ 0.001, two-way ANOVA with Tukey post-test. **(E)** NO production of non-infected (Control) or *T. gondii* (RH) infected J774-A1 **(F)** or RAW 264.7 cells for 24 h with normal medium or supplemented with different levels of [L]{.smallcaps}-arginine. Mean ± SEM (*n* = 3 experiments, each with 6 replicates). ^∗^*P* ≤ 0.05 and ^∗∗^*P* ≤ 0.01, ^∗∗^*P* ≤ 0.01, ^∗∗∗^*P* ≤ 0.001, ^∗∗∗∗^*P* ≤ 0.0001 one-way ANOVA with Tukey post-test, ^\#^*P* ≤ 0.05 comparing the "Control" or "Infected" bar with the respective "Normal medium" bar.](fmicb-09-01936-g001){#F1}

During host cell invasion *T. gondii* secretes important virulence factors including ROP16, which activates STAT 3 and STAT 6 in macrophages resulting in upregulation of arginase 1 (ARG1) ([@B6]). Induction of ARG1 competes with iNOS for the substrate [L]{.smallcaps}-arginine ([@B6]), hence this may be a mechanism of avoiding NO production. To determine if inhibition of NO production in activated macrophages was caused by substrate depletion, we supplemented the culture medium with increasing concentrations of [L]{.smallcaps}-arginine and evaluated NO production after 24 h of infection. Treatment of activated J774-A1 macrophages with increasing concentrations of [L]{.smallcaps}-arginine did not enhance NO production in control or infected cells, nor reverted the inhibition of NO production phenotype caused by *T. gondii* infection (**Figure [1E](#F1){ref-type="fig"}**). In contrast, incubation of activated RAW 264.7 macrophages with increasing concentrations of [L]{.smallcaps}-arginine enhanced NO production in control and infected cells, and yet it did not reverse the inhibition of NO production in infected cells (**Figure [1F](#F1){ref-type="fig"}**).

iNOS Expression in Infected Macrophages Is Dependent on Cell Line Type
----------------------------------------------------------------------

To examine whether the inhibition of NO production in activated J774-A1 macrophage was caused by protein degradation, iNOS expression was evaluated by different methods. iNOS showed variable levels of expression in activated non-infected J774-A1 macrophages based on IFA staining (**Figure [2A](#F2){ref-type="fig"}**). Following infection with *T. gondii* there were more iNOS negative cells at 24 h post-infection (**Figure [2A](#F2){ref-type="fig"}**). This finding was confirmed by analyzing the proportion of activated cells that were positive for iNOS in non-infected cells (Control) and *T. gondii* challenged cells (Non-infected or Infected) as depicted in **Figure [2B](#F2){ref-type="fig"}**. Although there was a tendency to decrease the number of iNOS positive cells in infected macrophages at 2 h, this effect was significant at 24 h post-infection (**Figure [2B](#F2){ref-type="fig"}**). Western blot (**Figure [2C](#F2){ref-type="fig"}** and **Supplementary Figure [1](#SMD1){ref-type="supplementary-material"}**) and densitometry analysis (**Figure [2D](#F2){ref-type="fig"}**) also confirmed inhibition of iNOS expression in cells infected for 24 h. However, reduction in iNOS expression was not observed at earlier time points after infection (**Figure [2D](#F2){ref-type="fig"}**).

![Immunofluorescence detection of iNOS in activated J774-A1 macrophages infected with *T. gondii*. **(A)** Detection of iNOS (green) in non-infected (Control) and in *T. gondii* (red) infected cells (DAPI - blue) at 2, 6, and 24 h post-infection. Scale bar = 10 μm. **(B)** Analysis of the proportion of iNOS positive or negative macrophages in non-infected (Control) and *T. gondii* infected cells at 2 and 24 h post-infection. Mean ± SEM (*n* = 4 experiments, each with 8 replicates). **(C)** Western blot detection of iNOS expression in non-infected (Control) and *T. gondii* infected (Infected) cells. β-actin was used as loading control. **(D)** Densitometry of western blots normalized to β-actin at 2 h post-infection. Mean ± SD (*n* = 3 experiments, each with 1 replicate). ^∗^*P* ≤ 0.05, two-way ANOVA with Tukey post-test, n.s (not significant).](fmicb-09-01936-g002){#F2}

We also analyzed iNOS expression after *T. gondii* infection of RAW 264.7 macrophages using similar IFA and Western blot analyses. The signal intensity of iNOS expression in RAW 264.7 cells was much higher, with all uninfected cells being uniformly positive (**Figure [3A](#F3){ref-type="fig"}** and **Supplementary Figure [2](#SMD1){ref-type="supplementary-material"}**). No difference in iNOS expression by IFA was observed between non-infected and infected RAW 264.7 macrophages at 24 h post-infection (**Figure [3A](#F3){ref-type="fig"}**). This finding was confirmed by analyzing the proportion of cells that were positive for iNOS. In non-infected and *T. gondii* challenged RAW 264.7 macrophage populations, most of the cells remained iNOS positive up to 24 h post-infection (**Figure [3B](#F3){ref-type="fig"}**). Similarly, no difference in iNOS expression between control and infected cells was observed by Western blot (**Figure [3C](#F3){ref-type="fig"}**) and densitometry analysis (**Figure [3D](#F3){ref-type="fig"}**) at different time points post-infection.

![Immunofluorescence detection of iNOS in activated RAW 264.7 macrophages infected with *T. gondii*. **(A)** Detection of iNOS (green) in non-infected (Control) and in *T. gondii* (red) infected cells (DAPI - blue) at 2, 6, and 24 h post-infection. Scale bar - 10 μm. **(B)** Analysis of the proportion of iNOS positive or negative macrophages in non-infected (Control) and *T. gondii* infected cells at 2 and 24 h post-infection. Mean ± SEM (*n* = 4 experiments, each with 8 replicates). **(C)** Western blot detection of iNOS expression in non-infected (Control) and *T. gondii* - infected (Infected) cells at different time intervals post-infection. β-actin was used as loading control. **(D)** Densitometry of western bolts normalized to β-actin at 2 h post-infection. Mean ± SD (*n* = 3 experiments, each with 1 replicate), n.s (not significant).](fmicb-09-01936-g003){#F3}

Evaluation of *T. gondii* Virulence Factors Do Not Influence Inhibition of NO Production
----------------------------------------------------------------------------------------

A number of previous virulence factors have been identified in *T. gondii* including a complex of ROP kinases consisting of ROP5, ROP17, and ROP18 that participates in defense of the parasitophorous vacuole by thwarting IRGs ([@B24]). To determine whether the inhibition of NO production in infected activated J774-A1 and RAW 264.7 macrophages was dependent on the ROP kinases, we examined the inhibition of NO production in activated macrophages infected with a series of mutants. Inhibition of NO production was similar in both macrophage cell lines at 24 h infection when comparing the parent RH line to a series of ROP deletion mutants (**Figures [4A,C](#F4){ref-type="fig"}**). We also examined the ability of a Δrop16 mutant to alter this phenotype, since this kinase has previously been shown to activate STAT3/STAT6 and hence activate ARG1 ([@B6]). The rop16 mutant showed a similar capacity to block NO production in activated J774-A1 and RAW 264.7 cells (**Figures [4A,C](#F4){ref-type="fig"}**). The various knockout parasites presented no deficiency in entry in activated J774-A1 or RAW 264.7 macrophages (**Supplementary Figure [3](#SMD1){ref-type="supplementary-material"}**).

![Analysis of ROP and ASP5, MYR1, and IST deletion mutants on the ability of *T. gondii* to inhibit NO production (nitrite in μM) of activated macrophages. **(A)** NO production of non-infected (Control) or activated J774-A1 cells infected with parental (RHΔku80 strain) or various ROP deletion strains of *T. gondii* at 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). ^∗∗∗∗^*P* ≤ 0.0001, one-way ANOVA with Tukey post-test. **(B)** NO production of non-infected (Control) or activated J774-A1 cells infected with parental (RHΔku80 strain) or Δasp5, Δmyr1, or Δist mutant strains of *T. gondii* at 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). ^∗∗∗∗^*P* ≤ 0.0001, one-way ANOVA with Tukey post-test. **(C)** NO production of non-infected (Control) or activated RAW 264.7 cells infected with parental (RHΔku80 strain) or various ROP deletion strains of *T. gondii* at 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). ^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01, ^∗∗∗^*P* ≤ 0.001, ^∗∗∗∗^*P* ≤ 0.0001, one-way ANOVA with Tukey post-test. **(D)** NO production of non-infected (Control) or activated RAW 264.7 cells infected with parental (RHΔku80 strain) or Δasp5, Δmyr1, and Δist mutant strains of *T. gondii* at 24 h post-infection. Mean ± SEM (*n* = 3 experiments, each with 12 replicates). ^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01, one-way ANOVA with Tukey post-test.](fmicb-09-01936-g004){#F4}

We also tested *T. gondii* mutants in the modulator IST that inhibits STAT1 transcription ([@B21]). These mutants had no effect on the NO inhibition phenotype (**Figures [4B,D](#F4){ref-type="fig"}**). Recently, the major role of the Golgi-associated protein, ASP5, and the parasitophorous vacuole (PV) associated protein, MYR1, in the cleavage and export of some dense granule effector proteins across the vacuole membrane into the host cell has been demonstrated ([@B10]; [@B17]). Therefore we examined the ability of mutants in these effectors to block the production of NO in activated macrophages. After infection, all knockout parasites were able to inhibit NO production of activated J774-A1 (**Figure [4B](#F4){ref-type="fig"}**) and RAW 264.7 macrophages (**Figure [4D](#F4){ref-type="fig"}**) similar to the parental parasite. The various knockout parasites presented no deficiency in entry in activated J774-A1 or RAW 264.7 macrophages (**Supplementary Figure [3](#SMD1){ref-type="supplementary-material"}**).

Discussion
==========

*Toxoplasma gondii* has many evasion mechanisms including the capacity to inhibit NO production of infected activated macrophages ([@B11]; [@B39], [@B40]; [@B29]; [@B33]). NO production inhibition, iNOS expression and the role of some *T. gondii* effectors were studied in parallel using two macrophage cell lines. Infection of both cell lines caused inhibition of NO production. However, only in J774-A1 macrophages was NO inhibition detected at early stages of infection (i.e., 2 h post-infection), while inhibition was seen starting at 6 h post-infection in both lines. Addition of extra [L]{.smallcaps}-arginine substrate to both macrophage lines did not change NO production inhibition, indicating that this result is not due to substrate limitation. Interestingly, reduction of iNOS expression after infection was only detected in J774-A1 cells, with RAW 264.7 presenting the same levels as non-infected cells. Finally, knockout parasites in known effectors were able to inhibit NO production similar to the parental strain. Our findings suggest that the inhibition of NO production of activated macrophages infected by *T. gondii* is a general phenomenon, but iNOS suppression varies depending on the macrophage cell line. In addition, it is likely that a novel parasite effector is responsible for this evasion mechanism.

*Toxoplasma gondii* infection causes ARG1 expression that competes with iNOS for [L]{.smallcaps}-arginine ([@B13]; [@B6]). However, extra [L]{.smallcaps}-arginine did not reverse NO production inhibition in either infected cell lines, indicating that the reduction in NO production is not due to substrate limitation. Following addition of [L]{.smallcaps}-arginine, J774-A1 produced the same amount of NO while RAW 264.7 macrophages responded to this addition by producing more NO. This finding is consistent with the differences in iNOS expression, and provides a further distinction in phenotypes between these two lines ([@B22]; [@B27]; [@B12]).

Previous report showed that NO production inhibition of *T. gondii* infected activated mice peritoneal macrophages was related to iNOS degradation ([@B39], [@B40]), which involves the proteasome in J774-A1 macrophages ([@B33]). Down modulation of iNOS expression was verified in infected J774-A1 but this was not observed in RAW 264.7 macrophages. These results suggest that the strategy adopted by *T. gondii* to inhibit NO production may be specific to the host cell, due to the intrinsic characteristics and origin of each macrophage cell line. The J774-A1 line was originally established from reticulum cell sarcoma ([@B23]) while the RAW 264.7 line from a tumor induced by Abelson murine leukemia virus ([@B34]) both in BALB/c mice. Furthermore, exposure of both cell lines to *Streptococcus iniae* induces a higher respiratory burst response in RAW 264.7 than in J774-A1 macrophage ([@B12]). Moreover, RAW 264.7 produces 30-fold higher TNF-α mRNA than J774-A1 after LPS stimulation ([@B22]). These differences help to explain the higher expression of iNOS in RAW 264.7 compared to J774-A1 macrophages. In addition, a gene expression profile study ([@B27]) shows that J774-A1 is closer to peritoneal mice macrophages than RAW 264.7, despite the fact that both cell lines were derived from transformed cells obtained from ascites ([@B34]). Our findings reveal that *T. gondii* infection can down-regulate NO production in these different macrophage cell lines, albeit by different mechanisms.

During host cell infection, *T. gondii* secrets the content of rhoptries and dense granules ensuring the establishment of infection and hijacking host cell-autonomous immunity ([@B41]). ROP and GRA proteins form complexes that protect *T. gondii* PV by avoiding recruitment of IRGs ([@B24]). GRA proteins are also exported across the PV altering important host functions ([@B21]). TgIST is a GRA effector that represses STAT1 transcription blocking gene expression induced by IFN-γ ([@B18]; [@B32]). In addition, the export and traffic of GRAs across the PV and into the host cell are dependent of ASP5 ([@B9]; [@B10]) and MYR1 ([@B17]). However, these virulence factors have not previously been evaluated for their ability to modulate other important host microbicidal systems such as NO production. Thus, knockout parasites were used to investigate whether some rhoptry proteins (ROP5, ROP16, ROP17, ROP18). The parasite ROP16 kinase has been implicated in modulating NO production in microglial cells and astrocytes ([@B6]). However, the knockout in ROP16 did not affect the down modulation of NO production in either of the macrophage cells lines studied here. Additionally, the ROP5-ROP17-ROP18 complex, which has been implicated in blocking IRG-mediated clearance, did not affect the down modulation of NO production in *T. gondii* -- infected cells. We also explored the roles of the GRA TgIST, or components of the PV membrane translocation system (ASP5, MYR1) for involvement in NO production control in infected macrophages. These GRA knockout parasites were able to inhibit NO production similar to the parental strain in J774-A1 and RAW 264.7 macrophages. These results indicate that the parasite effector that down modulates NO production is independent of TgIST, including other modulators that depend on the trafficking pathway based on ASP5 and MYR1.

Overall, our findings reveal that the strategy adopted by *T. gondii* to inhibit NO production in activated macrophages is independent of previously characterized virulence factors, such as the ROP5-ROP17-ROP18 complex, ROP16, GRA effectors, and the ASP5 and MYR1 export pathway. Thus, a possibly new parasite effector is involved in NO production inhibition in these cells. The mechanism causing NO production inhibition of macrophages infected by *T. gondii* varies depending on the host cell background: it involves reduction of iNOS expression in J774-A1 and iNOS impairment in RAW 264.7. This may be relevant to *in vivo* infections where *T. gondii* infects and needs to cope with distinct macrophage populations.
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ASP5

:   aspartyl protease 5

GRA

:   dense granule proteins

iNOS

:   inducible nitric oxide synthase

IRGs

:   immunity related GTPases

MYR1

:   myc regulation 1

NO

:   nitric oxide

ROP

:   rhoptry proteins

TgIST

:   *Toxoplasma gondii* inhibitor of STAT1-dependent transcription
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